192 related articles for article (PubMed ID: 22975816)
41. The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients.
Tong Y; Qian J; Li Y; Meng H; Jin J
Am J Hematol; 2007 May; 82(5):403-4. PubMed ID: 17133426
[TBL] [Abstract][Full Text] [Related]
42. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients.
Corso A; Mangiacavalli S; Varettoni M; Pascutto C; Zappasodi P; Lazzarino M
Leuk Res; 2010 Apr; 34(4):471-4. PubMed ID: 19674790
[TBL] [Abstract][Full Text] [Related]
43. A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma.
Ghobrial IM; Munshi NC; Harris BN; Shi P; Porter NM; Schlossman RL; Laubach JP; Anderson KC; Desaiah D; Myrand SP; Wooldridge JE; Richardson PG; Abonour R
Am J Hematol; 2011 Jul; 86(7):573-8. PubMed ID: 21630305
[TBL] [Abstract][Full Text] [Related]
44. [Development of an extramedullary plasmacytoma despite disappearing M protein in multiple myeloma by bortezomib treatment].
Koiso H; Tahara K; Osaki Y; Mawatari M; Sekigami T; Yokohama A; Saitoh T; Uchiumi H; Handa H; Tsukamoto N; Karasawa M; Nojima Y; Murakami H
Rinsho Ketsueki; 2009 Feb; 50(2):78-82. PubMed ID: 19265298
[TBL] [Abstract][Full Text] [Related]
45. Bortezomib-induced peripheral neuropathy in patients with multiple myeloma.
Berkowitz A; Walker S
Clin J Oncol Nurs; 2012 Feb; 16(1):86-9. PubMed ID: 22297012
[TBL] [Abstract][Full Text] [Related]
46. Bortezomib: new drug. A last resort in myeloma: modest efficacy, major risks.
Prescrire Int; 2005 Jun; 14(77):94-8. PubMed ID: 15981389
[TBL] [Abstract][Full Text] [Related]
47. [Bortezomib-associated acute congestive heart failure in a patient with multiple myeloma].
Aota Y; Gotoh A; Hanyu N; Honma T; Morisaki M; Yokoyama T; Kitagawa N; Komatsu N
Rinsho Ketsueki; 2015 Jan; 56(1):44-7. PubMed ID: 25745969
[TBL] [Abstract][Full Text] [Related]
48. Bortezomib-induced rhabdomyolysis in multiple myeloma.
Cibeira MT; Mercadal S; Arenillas L; Muntañola A; Salamero O; Bladé J
Acta Haematol; 2006; 116(3):203-6. PubMed ID: 17016040
[TBL] [Abstract][Full Text] [Related]
49. Cutaneous lesion induced by a subcutaneous administration of bortezomib.
Obeid KM; Ferrara R; Sharma M
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):284-6. PubMed ID: 22633164
[No Abstract] [Full Text] [Related]
50. Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma.
Bensinger WI; Jagannath S; Vescio R; Camacho E; Wolf J; Irwin D; Capo G; McKinley M; Potts P; Vesole DH; Mazumder A; Crowley J; Becker P; Hilger J; Durie BG
Br J Haematol; 2010 Feb; 148(4):562-8. PubMed ID: 19919652
[TBL] [Abstract][Full Text] [Related]
51. Bortezomib-induced severe hepatitis in multiple myeloma: a case report.
Rosiñol L; Montoto S; Cibeira MT; Bladé J
Arch Intern Med; 2005 Feb; 165(4):464-5. PubMed ID: 15738379
[TBL] [Abstract][Full Text] [Related]
52. Bortezomib in multiple myeloma.
Mateos MV; San Miguel JF
Best Pract Res Clin Haematol; 2007 Dec; 20(4):701-15. PubMed ID: 18070714
[TBL] [Abstract][Full Text] [Related]
53. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma.
Jagannath S; Durie BG; Wolf J; Camacho E; Irwin D; Lutzky J; McKinley M; Gabayan E; Mazumder A; Schenkein D; Crowley J
Br J Haematol; 2005 Jun; 129(6):776-83. PubMed ID: 15953004
[TBL] [Abstract][Full Text] [Related]
54. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.
Jagannath S; Barlogie B; Berenson J; Siegel D; Irwin D; Richardson PG; Niesvizky R; Alexanian R; Limentani SA; Alsina M; Adams J; Kauffman M; Esseltine DL; Schenkein DP; Anderson KC
Br J Haematol; 2004 Oct; 127(2):165-72. PubMed ID: 15461622
[TBL] [Abstract][Full Text] [Related]
55. Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
Chen MH; Qi C; Reece D; Chang H
Hum Pathol; 2012 Jun; 43(6):858-64. PubMed ID: 22047644
[TBL] [Abstract][Full Text] [Related]
56. Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity.
Lanzani F; Mattavelli L; Frigeni B; Rossini F; Cammarota S; Petrò D; Jann S; Cavaletti G
J Peripher Nerv Syst; 2008 Dec; 13(4):267-74. PubMed ID: 19192066
[TBL] [Abstract][Full Text] [Related]
57. Immune-mediated neuropathies in myeloma patients treated with bortezomib.
Ravaglia S; Corso A; Piccolo G; Lozza A; Alfonsi E; Mangiacavalli S; Varettoni M; Zappasodi P; Moglia A; Lazzarino M; Costa A
Clin Neurophysiol; 2008 Nov; 119(11):2507-12. PubMed ID: 18829381
[TBL] [Abstract][Full Text] [Related]
58. Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study.
Richardson PG; Chanan-Khan AA; Lonial S; Krishnan AY; Carroll MP; Alsina M; Albitar M; Berman D; Messina M; Anderson KC
Br J Haematol; 2011 Jun; 153(6):729-40. PubMed ID: 21534941
[TBL] [Abstract][Full Text] [Related]
59. [Clinical development of a proteasome inhibitor, bortezomib, for the treatment of myeloma and lymphoma].
Tobinai K
Rinsho Ketsueki; 2007 Jun; 48(6):451-7. PubMed ID: 17633092
[No Abstract] [Full Text] [Related]
60. Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma.
Sahebi F; Frankel PH; Farol L; Krishnan AY; Cai JL; Somlo G; Thomas SH; Reburiano E; Popplewell LL; Parker PM; Spielberger RT; Kogut NM; Karanes C; Htut M; Ruel C; Duarte L; Murata-Collins JL; Forman SJ
Biol Blood Marrow Transplant; 2012 Mar; 18(3):486-92. PubMed ID: 22198542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
